Pursuant to Regulation 30 and 33 of the SEBI (LODR) Regulations, 2015 we wish to inform that the board of directors at its meeting held tuesday 11th November, 2025 has inter alia considered ....

Revenue Growth 20pctPat Growth 25pctDebt Equity ThresholdNegative Operating CashflowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+9.6%Reaction day

₹1.98

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.9%+8.7% vs market

Pharmaceuticals peers, median of 157sector+0.8%+8.8% vs sector

On the reaction day the stock moved 8.7 pts more than Nifty Microcap 250 and 8.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+9.6+0.9+8.7+0.8+8.8

Next day

+20.2+0.8+19.4+0.5+19.7

+31.8+0.7+31.1+0.4+31.5

+25.3+1.3+23.9+0.4+24.8

+19.2+0.5+18.7-0.1+19.3

+13.6+0.4+13.3-0.6+14.2

+13.1-1.5+14.6-1.2+14.3

15d

+8.1-2.4+10.5-1.8+9.9

+3.0-4.4+7.4-2.6+5.6

+9.1-7.2+16.3-5.4+14.5

+3.5-5.0+8.5-6.0+9.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vivanza Biosciences reported its Q2 FY26 (quarter ended September 30, 2025) standalone and consolidated results on November 11, 2025. Standalone revenue from operations surged to ₹5,373.18 lacs from just ₹158.33 lacs in Q2 FY25, with profit after tax of ₹46.21 lacs versus ₹0.53 lacs a year ago. For H1 FY26, standalone revenue reached ₹6,155.24 lacs and PAT ₹48.06 lacs, compared to ₹201.11 lacs and ₹23.18 lacs respectively in H1 FY25. The consolidated results showed revenue of ₹5,535.78 lacs (Q2) and PAT of ₹56.29 lacs (Q2). The board accepted the resignation of CS Siddhi Shah and appointed CS Chaitra Arora as the new Company Secretary & Compliance Officer. The board also approved an alteration to the company's main objects clause to expand into manufacturing and trading of plastic polymer films, plastic/paper bags, and flexible packaging materials, subject to shareholder approval via postal ballot.

Likely market impact

The dramatic revenue and profit jump reflects a very low prior-year base rather than steady growth, so investors should watch for sustainability. The proposed shift into plastic/paper packaging is a major strategic diversification away from core pharma and could change the company's risk profile. Total borrowings of about ₹728 lacs against equity of ₹450 lacs (standalone) imply a high debt-to-equity ratio of ~1.6x, and standalone operating cash flow was negative ₹56 lacs in H1 FY26 — both are red flags worth tracking.